



MOREPEN



May 13, 2013

National Stock Exchange Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra East
Mumbai- 400 051

Dear Sir,

Sub: Copy of the Press Release

Please find attached the copy of the press release issued by the company.

This is for your information and record please.

Thanking you,

Yours faithfully
For Morepen Laboratories Limited


(Rahul)
Company Secretary

Encl: As above.

Morepen Laboratories Limited

Corp. Off.: 4th Floor, Antriksh Bhawan, 22 K.G. Marg, New Delhi - 110 001. INDIA
Tel.: +91-11-23324443, 23712025 Fax: +91-11-23722422.
E-mail : corporate@morepen.com Website : www.morepen.com

Plant & Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P) 173 205
Tel. : +91-01795-276201-03 Fax : +91-1795-276204
E-mail : plants@morepen.com

PRESS RELEASE

Morepen Laboratories Limited, having USFDA approved facilities in Himachal Pradesh for manufacturing LORATADINE & DESLORATADINE has registered recorded Sales revenues of Rs. 296 Crores during the current financial ending March 2013. The company has posted a growth of 13% over the last year revenues of Rs. 261 Crores.

API business of the company during the year was at Rs. 191 Crores, recording a growth of 13% over the last year. The major contribution is coming from API Business .

Under its API business the company has doubled the capacity of its anti-asthmatic drug Montelukast Sodium to 24MT/annum and recorded the highest topline of Rs. 54.5 Crores in F.Y. 2012-13. Morepen is the largest manufacturer of Montelukast in India & it is expected to show a very good growth in the coming years. The company has also got registered this product in China, Korea & Thailand.

Its formulation, diagnostics and contract manufacturing business at Rs. 105 Crores have also recorded impressive growth of 17% in their sales revenues. Morepen has established its "Home Health" brand in the home diagnostics field in the domestic market & has taken its position as leading domestic brand in the category of Blood Pressure Monitors, Glucometers , Digital Thermometers & Weighing Scales.

OTC business carried out under 100% owned subsidiary "Dr. Morepen" has recorded sales revenue of Rs. 25.8 Crores, a growth of 11% over last year. While Dr. Morepen 'Burnol' remains the leading product in the Burn category , Lemolate is getting a good hold in the Cold & Fever market .

The Company has gained domestic market share by 22 % while exports have grown by 6% . Current Year EBIDTA at Rs. 31.6 Crores have shown a growth of more than 69% over last year EBIDTA of Rs. 18.7 Crores. Cash profits at Rs. 20 Crores have gone up by 87% over last year of Rs. 10.7 Crores. The company is back on the growth track & targeting to launch some of the new molecules in the field of anti-diabetic & anti-hypertensive category.

